|Year : 2018 | Volume
| Issue : 1 | Page : 41-45
Expression of Bax and Bcl2 genes in peripheral blood lymphocytes of patients with differentiated thyroid cancer
Zari Hamivand1, Gholamhassan Haddadi2, Reza Fardid3
1 Department of Radiology, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
2 Ionizing and Non-Ionizing Radiation Protection Research Center (INIRPRC), Shiraz University of Medical Sciences, Shiraz; Department of Medical Physics, Fasa University of Medical Sciences, Fasa, Iran
3 Department of Radiology, School of Paramedical Sciences; Ionizing and Non-Ionizing Radiation Protection Research Center (INIRPRC), Shiraz University of Medical Sciences, Shiraz, Iran
|Date of Submission||26-Aug-2017|
|Date of Decision||13-Nov-2017|
|Date of Acceptance||14-Nov-2017|
|Date of Web Publication||12-Mar-2018|
Dr. Reza Fardid
Department of Radiology, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Context: Thyroid cancer is the most common endocrine malignancy worldwide. Iodine-131 is used in the treatment of thyroid cancer with dosage of 100 mCi. In the medical applications of ionizing radiation besides the advantages such as diagnosis and treatment of diseases, the risks arising from exposure should be considered as well. Aims: The present study aimed to evaluate the changes in expression levels of apoptotic Bax and Bcl-2 and the ratio of Bax/Bcl-2, in the peripheral blood lymphocytes (PBLs) of patients with differentiated thyroid cancer (DTC). Settings and Design: This study was conducted on fifty thyroid cancer patients who had undergone surgery and were under treatment with 100 and 150 mCi doses. Subjects and Methods: Blood samples were taken from the patients, one before iodine treatment and another 48 h after therapy. Bax and Bcl-2 gene expression levels were measured by using real-time reverse transcriptase polymerase chain reaction. Statistical Analysis Used: The data were analyzed using one-way analysis of variance followed by samples t-test and independent samples t-test. Results: Significant changes were observed in the percentage of apoptotic cells, in groups, after radioiodine therapy compared with before treatment. The ratio of Bax/Bcl-2 in both groups showed a significant increase (P < 0.001). The relative expression level of Bax gene showed a significant increase in comparison with the control group. Conclusions: Iodine therapy reduced expression of Bcl-2 and a significant expression of Bax and finally increased the ratio of Bax/Bcl-2. Iodine therapy led to apoptosis in the PBLs of patients with DTC. Therefore, it can be suggested that this method can be useful for monitoring and detecting destructive effects of ionizing radiation in nuclear medicine patients.
Keywords: Bax, Bcl2, differentiated thyroid cancer, gene expression, peripheral blood lymphocytes
|How to cite this article:|
Hamivand Z, Haddadi G, Fardid R. Expression of Bax and Bcl2 genes in peripheral blood lymphocytes of patients with differentiated thyroid cancer. J Med Phys 2018;43:41-5
|How to cite this URL:|
Hamivand Z, Haddadi G, Fardid R. Expression of Bax and Bcl2 genes in peripheral blood lymphocytes of patients with differentiated thyroid cancer. J Med Phys [serial online] 2018 [cited 2021 Apr 13];43:41-5. Available from: https://www.jmp.org.in/text.asp?2018/43/1/41/227062
| Introduction|| |
The differentiated thyroid cancer (DTC) comes for 1%–2% of malignant cancer in human. Its annual incidence is estimated 2–3.8 for women and 1.2–2.6 for men/100,000 persons. Its outbreak has increased in the recent decades.
This cancer derives from either the classified epithelial follicular cells in the form of cancer with high differentiation (including papillary cancers and thyroid follicular, the thyroid cancer with low differentiation and anaplasic) or the parafollicle cells as generator of calcitonin (such as medullary cancer). Generally, the differentiated forms of thyroid cancer have a slow progression trend; their treatment includes taking measures such as surgery, using radioactive iodine, and inhibiting TSH hormone. Radioactive iodine-131 has been used in the treatment of malignant thyroid since 1940. The radioactive 131 iodine is one of the iodine isotopes with half-life of 8 days and is released by the distribution of beta particles along with gamma radiation; and changes into stable xenon 131. In the medical applications of ionizing radiation besides the advantages such as diagnosis and treatment of diseases, the risks arising from exposure should be considered too.
Ionizing radiation has been known as causing oxidative stress by generating active oxygen types and free radicals in the tissues and irradiated cells. These free radicals react with DNA, existing lipids in the nucleus and membrane.,
Significant changes in the structure and practice of DNA (failure of double-stranded DNA) and membrane (hard) lead to cell death through apoptosis., Apoptosis is induced by a variety of toxic insults including growth factor deprivation and ionizing radiation. Ionizing radiation damages DNA and is one agent that induces apoptosis in certain cells, including human lymphocytes. In the early stages of apoptosis, it is measured., Phosphatidylinositol serine transfers from the inner surface to the outer surface of the cell membrane and the integration of cell membrane has been preserved. In the late apoptosis stages of apoptosis, the integration of cell membrane is destroyed, and the time of cell death or apoptosis depending on the type of cell has been estimated from a few hours to a few days., The programmed cell death precisely depends on action and reaction of some gene products that activate or inhibit the process of cell suicide. Two large gene families including Caspases and Bcl-2 are involved in the path of apotheosis. The Bcl-2 family has two protein groups including apoptosis promoter and inhibitor of apoptosis. The average ratio of these proteins determines a cell destiny. The Bcl-2 protein is placed in the cover of core and mitochondria; and it functions through the connection to Bax. The Bax protein in terms of structural is Bcl-2 homologous, and it is considered to be a promoter of apoptosis that is placed in the cytoplasm or the cellular membrane, and hence, in terms of performance, this antagonist protein has a protective role for Bcl-2. The caspase molecules are generated in the form of prefabricate and just after receiving a death signal by cell, they are activated.
Caspase 3 is an executive caspase that is activated by the starter caspases and breaks the survival and integrity of proteins. The death signals cause the setting up the apoptosis proteins family of Bcl-2, especially Bax. These proteins cause the release of cytochrome C from mitochondria to out. The release of mitochondrial cytochrome C into the cytoplasm and its subsequent association with the Apaf-1 protein is thought to be an absolute requirement for the activation of caspase-9, the apical caspase in the mitochondrial pathway of apoptosis.,
In another study in 2013, conducted by Verne Dick et al., apoptosis and micronuclei (MN) were investigated as the reflection of cytogenetic injury in the blood lymphocyte of 18 patients suffered from thyroid cancer under treatment with 100 and 150 mill curie doses. As apoptotic cells, using Annexin V-FITC/7-AAD kit and frequency of MN was assessed by MN assay. In this study, after radioiodine therapy in thyroid cancer patients, increase of primary apoptosis and MNs was observed.
The aim of this study was to investigate the expression pattern of some inhibitors of Bcl-2 cell death and inducers of Bax cell death in patients under iodine therapy with different doses.
| Subjects and Methods|| |
This research was approved by the ethical committee of Shiraz University of Medical Sciences. The consent form was presented to patients and voluntarily read and signed. The studied population included fifty patients with thyroid cancer with the mean age of 39.08 ± 9.5; they had undergone thyroidectomy and were under treatment in the nuclear medicine department of Shiraz Namazi Hospital. Blood samples were taken before radioiodine therapy and 48 h after iodine therapy. Blood samples (2 ml of peripheral blood from patients) were collected in heparinized tubes. These samples were used for the measurement of Bax and Bcl-2 expression levels using real-time (RT) reverse transcriptase polymerase chain reaction (PCR). At first, separation of lymphocytes was made using the ficoll of innotrain, Germany, based on the standard protocol. The blood was washed with the buffer of phosphate saline with the same volume and then, 4 ml volume (blood and phosphate-buffered saline [PBS]) was added to 2 ml ficoll and centrifuged for 20 min with 3000 RPM. The separated lymphocytes after three times of washing with PBS were centrifuged for 10 min in 1400 RPM g. The surface layer was thrown out and the extracted lymphocytes were mixed with 500 PBS μl.
RNA preparation and quantification
After isolation of the lymphocytes from the peripheral blood samples, total RNA was extracted from blood samples with the RNX plus extraction kit (CinnaGene, Iran), according to the manufacturer's protocol and stored at −20°C. For extracting of RNA from chloroform and isopropanol and wash it, 75% ethanol was used. The concentration and quality of RNA were determined by measuring the absorbance by spectrophotometer system (Bekman, USA) at 260 nm (A260) and A260/A280 ratio, respectively.
cDNA synthesis and real-time quantitative polymerase chain reaction
Before cDNA synthesis, to remove pollution of RNA with DNA, the DNase I kit (Thermo Science, USA) was used. The synthesis of cDNA was done by using RevertAid First Strand cDNA Synthesis kit (Fermentase, lithuania) and based on the manufacturer's instruction. The used designed primers of Bax, Bcl-2, and B2 m gene are shown in [Table 1]. The B2 m gene was used as the endogenous reference. The RT quantitative-PCR (QPCR) was done by CYBR Green kit (yekta tajhiz, Iran). The QPCR were done in cycle including: 2 min at 95°C for initial denaturation, and then, forty cycles of denaturation for 30 s in 95°C, annealing for 40 s in 57°C, with extension for 30 s in 72°C. The PCR products were separated on 2% agarose gel, and they were visible with ethidium bromide; then, they were evaluated by using trans-luminator advice UV (Uvidoc, UK). Target genes were quantified relative to the reference gene using the mathematical model described by computer tomography.
Verification polymerase chain reaction and primer design
To verify Bax, Bcl-2, and B2 m primers with 169, 153, and 87 base pair (bp) band lengths, PCR was performed with a cDNA sample. Five microliter of PCR product was loaded on 2% agarose gel. The distinctly mentioned band lengths of each gene were visible after ethidium bromide staining. [Figure 1] depicts the electrophoresis image of the three primers Bcl-2 ‛Bax and B2 m (Bcl-2, 153 bp, Bax, 153 bp, and B2 m 87 bp).
|Figure 1: Electrophoresis image of the designed Bcl-2, and Bax primers (Bcl-2, 153 bp and Bax, 169, B2m 87 bp), which is visible in the image|
Click here to view
The data were analyzed using one-way analysis of variance followed by samples t-test and independent samples t-test. The values of P < 0.05 were considered statistically significant.
| Results|| |
The changes in relative expression level of Bax and Bcl-2 genes [Figure 2] shows the relative expression level of Bax gene 48 h after iodine therapy, at a dose of 100 and 150 mci. The relative expression level of Bax gene at a dose of 100 and 150 mci showed a significant increase in comparison with before iodine therapy (P = 0.0001).
|Figure 2: The relative expression level of Bax gene 48 h after the iodine therapy at doses of 100 and 150 mCi|
Click here to view
As observed in [Figure 3], in two groups a significant decrease was found in the expression level of Bcl-2 in comparison with the control group (P < 0.05). The relative expression level of Bcl2 gene at a dose of 100 and 150 mCi showed a significant reduction in comparison with before iodine therapy.
|Figure 3: The relative expression level of Bcl2 gene 48 h after the iodine therapy at doses of 100 and 150 mCi|
Click here to view
[Figure 4] shows the relative expression level of Bax/Bcl-2 ratio 48 h after the iodine therapy at doses of 100 and 150 mCi). The ratio of Bax/Bcl-2 in after iodine therapy in comparison with before treatment led to a significant increase in the Bax/Bcl-2 ratio.
|Figure 4: The relative expression level of Bax/Bcl-2 gene 48 h after the iodine therapy at doses of 100 and 150 mCi|
Click here to view
[Figure 5] shows the relative expression level Bax, Bcl2, and Bax/Bcl-2 ratio 48 h after iodine therapy at different doses. At a dose of 150 mCi after iodine therapy, a significant increase was showed in the expression level of Bax comparison with dose 100 mci. We observed a significant increase in the ratio of Bax/Bcl-2 at a dose of 150–100 mci. It can be concluded that, at higher doses, expression of the apoptotic gene will increase and the percentage of apoptotic cells will be greater. [Table 2] and [Table 3] show the relative expression of Bax and Bcl-2 genes and Bax/Bcl-2 ratio of two therapeutic doses 48 h after iodine therapy. The relative expression level of Bax gene in both groups showed a significant increase after radioiodine therapy compared with before treatment. Moreover, the relative decrease in gene expression of Bcl-2, after the iodine treatment in both groups was statistically significant (P < 0.05). The ratio of the Bax/Bcl-2 in both groups showed a significant increase (P < 0.05).
|Figure 5: The relative expression level of Bax/Bcl-2 gene 48 h after the iodine therapy at doses of 100 and 150 mCi|
Click here to view
|Table 2: Comparison of gene expression BCL-2 and BAX before and 48 hours after radioiodine therapy in the dose of 100 mCi|
Click here to view
|Table 3: Comparison of gene expression BCL-2 and BAX before and 48 hours after radioiodine therapy in the dose of 150 mCi|
Click here to view
As shown in [Table 4], we examined the effect of two different doses of the gene expression of apoptosis. At a dose of 150 mCi, there was an increase in the dose of 100 mCi of the Bax gene expression. Bcl-2 levels also significantly decreased in a dose of 150 mCi to 100 mCi dose and this reduction was significant (P = 0.0005).
|Table 4: Comparison of gene expression BCL-2 and BAX in human lymphocytes at a dose of 100 and 150 mCi|
Click here to view
Furthermore, we observed a significant increase in the ratio of Bax/Bcl-2 at a dose of 150–100 mci and it can be concluded that, at higher doses, expression of the apoptotic gene will increase and the percentage of apoptotic cells will be greater.
| Discussion|| |
The 131 iodine is applicable in the thyroid cancers with a dosage higher than 100 mCi. Iodine in the patients that have undergone thyroidectomy is applied for the destruction of the remaining thyroid with probable metastases. Lymphocytes are easily eliminated as high-sensitivity cells in patients treated with radioactive iodine. Apoptosis is a reaction of cytogenic damage in the cells, and in this study, the expression of apoptosis genes was compared before and after iodine therapy. The purpose of this study was to investigate the effect of iodine therapy on the changes of apoptosis levels and expression of apoptosis genes.
Based on the obtained results of this study, the percent of apoptosis lymphocytes, 48 h after iodine therapy in comparison with before treatment shows that the increased level can be attributed to the increase in Bax gene expression in both groups which received 100 and 150 mCi. In addition, increase in the expression of the ratio of Bax/Bcl2 is an effective factor for incidence of apoptosis.
According to the results of a study conducted by Cui et al., it was shown that after 4 h exposure of all the body to 2–8 gray gamma radiation, the apoptosis lymphocytes increased rapidly, and expression of Bax gene in 24 h after radiation reached its maximum amount. The Bcl-2 expression reduces after passing 3 h after radiation, and the reduction reaches its minimum amount 24 h after that. This finding is consistent with the obtained results of our research; in the conducted study, the gamma arising from iodine 131 caused generation of apoptosis, increase of Bax gene expression and reduction of Bcl-2 in 48 h after prescribing iodine.
In another study done by Mehdi Mogharrabi et al. on patients with thyroid cancer, the injuries of radiation cytology to the peripheral blood lymphocytes (PBLs) were investigated by using the MN test. The blood samples before iodine therapy and 1 week after that were taken by receiving the dosages of 100 and 150 mCi. As MN was abundant, a week after iodine therapy, it was seen that it was an indirect marker of chromosomal abnormalities and radiation injury. This was similar to the obtained result of our study. MN and apoptosis are raised as cytogenic damages arising from radiation. The study results showed iodine therapy caused the effect of apoptosis, and its gene expression.
| Conclusions|| |
Iodine therapy reduces the relative expression of anti-apoptotic Bcl-2, and pro-apoptotic Bax gene expression was increased significantly. The ratio expression of Bax/Bcl-2 in doses of 100 and 150 mCi showed a significant increase. Apoptosis in PBLs after treatment with 100 or 150 mCi iodine-131 was significantly higher than before treatment. Patients with DTC have a significantly higher level of apoptosis in PBLs after iodine therapy. Based on the results of this study, radioiodine therapy in patients with thyroid cancer has led to increased apoptosis as a marker of cytogenetic damage.
Therefore, it can be suggested that this method can be useful for monitoring and detecting destructive effects of ionizing radiation in nuclear medicine patients.
The present article was financially supported by Shiraz University of Medical Sciences, Shiraz, Iran Grants No. 11087. The authors would like to thank Center for Development of Clinical Research of the Nemazee Hospital for statically analysis assistance and editing the manuscript.
Financial support and sponsorship
Shiraz University of Medical Sciences.
Conflicts of interest
There are no conflicts of interest.
| References|| |
Agate L, Lorusso L, Elisei R. New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. J Endocrinol Invest 2012;35:3-9.
Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control 2006;13:119-28.
Saha GB. ) Quality control of radiopharmaceuticals. In: Fundamentals of nuclear pharmacy. 5th
ed. New York: Springer; 1998. p. 151-74.
Chilton HM, Witcofski RL. Nuclear Pharmacy: An Introduction to the Clinical Application of Radiopharmaceuticals. Philadelphia, PA: Lea and Febiger; 1986.
Li LB, Wang JP, Yu XR, He SS, Yu FH, Ding CH, et al.
Medical radiation usage and exposures from medical X ray diagnosis in Shandong province of China. Radiat Prot Dosimetry 2001;93:261-6.
Mikkelsen RB, Wardman P. Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms. Oncogene 2003;22:5734-54.
Tominaga H, Kodama S, Matsuda N, Suzuki K, Watanabe M. Involvement of reactive oxygen species (ROS) in the induction of genetic instability by radiation. J Radiat Res 2004;45:181-8.
Verma SP, Sonwalkar N. Structural changes in plasma membranes prepared from irradiated Chinese hamster V79 cells as revealed by Raman spectroscopy. Radiat Res 1991;126:27-35.
Elia MC, DeLuca JG, Bradley MO. Significance and measurement of DNA double strand breaks in mammalian cells. Pharmacol Ther 1991;51:291-327.
Lizard G, Fournel S, Genestier L, Dhedin N, Chaput C, Flacher M, et al.
Kinetics of plasma membrane and mitochondrial alterations in cells undergoing apoptosis. Cytometry 1995;21:275-83.
Azimian H, Bahreyni-Toossi MT, Rezaei AR, Rafatpanah H, Hamzehloei T, Fardid R, et al.
Up-regulation of bcl-2 expression in cultured human lymphocytes after exposure to low doses of gamma radiation. J Med Phys 2015;40:38-44.
] [Full text]
Bahreyni-Toossi MT, Fardid R, Rezaee A, Sadr-nabavi A, Rafatpanah H, Bolbolian M. Expression of apoptotic genes can distinguish radiation workers from normal population. Int J Low Radiat 2011;8:388-99.
Vandaele L, Mateusen B, Maes DG, de Kruif A, Van Soom A. Temporal detection of caspase-3 and -7 in bovine in vitro
produced embryos of different developmental capacity. Reproduction 2007;133:709-18.
Jousan FD, de Castro E Paula LA, Brad AM, Roth Z, Hansen PJ. Relationship between group II caspase activity of bovine preimplantation embryos and capacity for hatching. J Reprod Dev 2008;54:217-20.
Opiela J. Apoptosis in preimplantation bovine embryos and methods used for its detection. Ann Anim Sci 2009;9:3-16.
Gopisetty G, Ramachandran K, Singal R. DNA methylation and apoptosis. Mol Immunol 2006;43:1729-40.
Tsujimoto Y, Shimizu S. Bcl-2 family: Life-or-death switch. FEBS Lett 2000;466:6-10.
Spanos S, Rice S, Karagiannis P, Taylor D, Becker DL, Winston RM, et al.
Caspase activity and expression of cell death genes during development of human preimplantation embryos. Reproduction 2002;124:353-63.
Nagata S. Apoptotic DNA fragmentation. Exp Cell Res 2000;256:12-8.
Vrndic O, Milosevic-Djordjevic O, Djurdjevic P, Jovanovic D, Mijatovic L, Jeftic I, et al.
Radioiodine therapy accelerates apoptosis in peripheral blood lymphocytes of patients with differentiated thyroid cancer. Neoplasma 2013;60:568-75.
Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000;21:485-95.
Cui YF, Ding YQ, Xu H, Jiang ZJ, Liu XL, Dong B, et al.
Relationship between apoptosis of mouse thymic lymphocytes and expressions of BAX, BCL-2 and BCL-XL after gamma-ray radiation with lethal dose. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2004;20:750-3.
Hooman A, Mogharrabi M, Solooki M, Mosaffa N, Tabeie F, Shafiee B, et al
. Radioiodine therapy induced cytotoxicity in patients with differentiated thyroid carcinoma. Int J Endocrinol Metab 2008;2008:135-9.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5]
[Table 1], [Table 2], [Table 3], [Table 4]